Navigation Links
Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease
Date:6/22/2009

l.

European Phase 3 Registration Trial Update

Amicus and its partner, Shire Human Genetic Therapies, Inc. (Shire HGT), have completed a series of discussions with the European Medicines Agency (EMEA). Based on feedback from the EMEA, the Companies expect a separate clinical study will be required for Amigal registration in Europe.

The EMEA has recommended a registration trial evaluating the safety and efficacy of Amigal in males and females with Fabry disease as compared to enzyme replacement therapy (ERT). The Agency agrees that the trial may enroll subjects currently receiving ERT. The recommended primary endpoint is renal function as measured by glomerular filtration rate (GFR) and the recommended primary analysis is a comparison of outcomes between the Amigal and ERT groups using descriptive statistics.

Amicus and Shire HGT are reviewing the final EMEA feedback and will provide an update regarding plans for registration in Europe in the second half of 2009.

About Amigal

Amigal has undergone clinical testing in a series of Phase 2 studies. Twenty-six male and female subjects were included in these studies and studied initially for either 12 or 24 weeks. Twenty-three of the 26 subjects continue to receive treatment in an ongoing extension study designed to evaluate the long-term safety and efficacy of Amigal. Fifteen of the 23 subjects have been on treatment for at least two years and five subjects have been on treatment for more than three years.

Results from the Phase 2 and the extension study were presented in March 2009 at the American College of Medical Genetics (ACMG) Annual Meeting in Tampa, FL. Specifically, Amicus reported that treatment with Amigal was generally well-tolerated, with no drug-related serious adverse events. The most common adverse events were headache, arthralgia and diarrhea. In s
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
11. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/17/2013)... 17, 2013 Perrigo Company (NYSE: ... a definitive agreement to acquire and has completed the ... portfolio from Fera Pharmaceuticals, LLC and its affiliates (Fera), ... -based specialty pharmaceutical company. The acquired portfolio, including nine ... net revenues during calendar year 2012. Terms of the ...
(Date:6/17/2013)... -- Breezy , a portfolio company of ... week using a platform technology enabling innovative treatment of mouth-cavity ... is being sold in major Israeli pharmacy chains and will ... Israel follows similar successful product launches ... earlier this year, with a repeat order from ...
(Date:6/17/2013)... June 17, 2013 Johnson & Johnson ... definitive agreement to acquire Aragon Pharmaceuticals, Inc., a ... drugs to treat hormonally-driven cancers. ... Aragon,s lead product candidate is a second generation ... development for castration resistant prostate cancer (CRPC). ...
Breaking Medicine Technology:Perrigo Company Acquires Ophthalmic Product Portfolio From Fera Pharmaceuticals, LLC For An Upfront Payment Of $93 Million 2Perrigo Company Acquires Ophthalmic Product Portfolio From Fera Pharmaceuticals, LLC For An Upfront Payment Of $93 Million 3A Big "LIKE" for Oral Hygiene 2Johnson & Johnson Announces Definitive Agreement To Acquire Aragon Pharmaceuticals, Inc. 2Johnson & Johnson Announces Definitive Agreement To Acquire Aragon Pharmaceuticals, Inc. 3
... American Medical Systems® (AMS) (Nasdaq: ... and therapies for male and female pelvic health, today ... Program (STEP) in Europe. The program is designed to ... about solutions for the treatment of erectile dysfunction (ED) ...
... CHICAGO, Jan. 14, 2011   The Cleveland Clinic and ... support the Clinic,s effort to become a clinically integrated ... together the Cleveland Clinic Hospitals, physicians, and more than ... Cleveland Clinic, through its Community Physician Partnership (CPP), recognized ...
Cached Medicine Technology:American Medical Systems Launches STEP Patient Education Program in Europe 2American Medical Systems Launches STEP Patient Education Program in Europe 3Valence Health Selected by Cleveland Clinic to Support Clinical Integration Program 2
(Date:6/18/2013)... 2013 The new swab, designed for ... through the tip allowing for faster collection of infant ... Swab (SIS) can be tested for cortisol, cotinine, ... The diameter of the Salimetrics Infant Swab has been ... to access more saliva in the newborn’s mouth and ...
(Date:6/17/2013)... Alonso Krangle LLP, an experienced personal injury ... and their co-counsel, the Zalkin Law Firm, announce they have ... firms filed on behalf of a Brooklyn man. According ... awarded $3.5 million to the Plaintiff, who was allegedly sexually ... finding in his favor, the Plaintiff told the New York ...
(Date:6/17/2013)... 2013 Vince Del Monte and Ben Pakulski are ... last year and it will only be around for the next ... Ryan Davids has released an updated Hypertrophy Max review to help ... Hypertrophy Max review here . , Davids says, "Vince Del Monte ... this 4 day sale as an extra incentive for people to ...
(Date:6/17/2013)... matter brain abnormalities in some patients after mild traumatic ... Alzheimer,s dementia, according to a new study published online ... of MTBI bear a striking resemblance to those seen ... Saeed Fakhran, M.D., assistant professor of radiology in the ... of Medicine. "Additional research may help further elucidate a ...
(Date:6/17/2013)... Daily Gossip Magazine has taken readers’ ... review of the Tinnitus Miracle treatment published ... natural treatment that Coleman suggests and the ... it. , Based on the information provided by nutritionists ... suggested by Thomas Coleman is different from others ...
Breaking Medicine News(10 mins):Health News:Salimetrics Redesigns Infant Swab for Faster, Easier Collection 2Health News:Child Sexual Abuse Lawsuit Victim Awarded $3.5 Million by Brooklyn Supreme Court Referee, Plaintiff Represented by Alonso Krangle LLP 2Health News:Child Sexual Abuse Lawsuit Victim Awarded $3.5 Million by Brooklyn Supreme Court Referee, Plaintiff Represented by Alonso Krangle LLP 3Health News:Updated Hypertrophy Max Review Released for Vince Del Monte and Ben Pakulski's Hypertrophy Max Training Program 2Health News:Concussion patients show Alzheimer's-like brain abnormalities 2Health News:Concussion patients show Alzheimer's-like brain abnormalities 3Health News:Thomas Coleman's Tinnitus Miracle Treatment Review Discloses Alternative Natural Cure 2
... researchers at the Mayo Clinic it was found that surgical ... effective when compared to the conventional open surgery. // ... the vagina after a hysterectomy. The results of the surgery ... United States, one out of nine women will undergo hysterectomy, ...
... of bacteria could explain the relationship between periodontal disease ... study published in the Journal of Periodontology. // ... higher in the ACS group for the combination of ... T. denticola. Specifically, the findings suggest that T. denticola, ...
... genetic variation, along with inflammatory factors and smoking, significantly ... degeneration, according to a study.// ,Age-related macular degeneration ... loss in the elderly of the Western world, according ... a role in AMD, and inflammation also may be ...
... migraines with aura (associated neurologic symptoms such as temporary ... attack, ischemic stroke, angina and death due to ischemic ... a migraine history. In contrast, migraine without aura, the ... increased risk of any cardiovascular event. ...
... University of California, Davis, M.I.N.D. Institute have discovered that ... in the amygdala//, a part of the brain involved ... director of the UC Davis M.I.N.D. Institute, and former ... samples of neurons in the amygdala of nine postmortem ...
... decades, parents and pediatricians have relied on humid air to ... common childhood condition that sometimes// sends worried families to the ... the long relied-on remedy has little medical benefit. ... shower in the bathroom. Or you get them to boil ...
Cached Medicine News:Health News:New Laparoscopic Surgery to Correct Vaginal Vault Prolapse Is Effectual Than the Conventional Surgery 2Health News:Link between Periodontal Bacteria and Heart Disease Established 2Health News:Genetic Variation Linked to Age-Related Macular Degeneration 2Health News:Migraines with Aura Associated with Increased Risk for Cardiovascular Disease 2Health News:Researchers Find Fewer Neurons in the Amygdala of Males with Autism 2Health News:Researchers Find Fewer Neurons in the Amygdala of Males with Autism 3Health News:Humid Air is Little Help for Croup's Barking Cough 2Health News:Humid Air is Little Help for Croup's Barking Cough 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: